论文部分内容阅读
胃肠间质瘤(gastrointestinal stromal tumor,GIST)的诊断和治疗已日趋标准化和规范化。近10余年来,随着分子水平发病机制的揭示和小分子酪氨酸激酶受体抑制剂的成功应用,GIST已经成为精准医疗时代最经典的实体肿瘤靶向治疗成功范例之一。2016年2月,美国国立综合癌症网络(NCCN)发布了最新版的《软组织肉瘤临床实践指南(2016年第2版)》,与既往版本相比,新版指南中GIST部分内容突出了野生型GIST规范化诊断与治疗,并在<2 cm的胃极小GIST的随访策略及GIST的恶性潜能评估等方面做出了部分调整。
The diagnosis and treatment of gastrointestinal stromal tumor (GIST) have become increasingly standardized and standardized. For more than 10 years, with the revelation of the molecular pathogenesis and the successful application of small molecule tyrosine kinase receptor inhibitors, GIST has become one of the most successful examples of solid tumor targeted therapy in the era of precision medical treatment. In February 2016, the National Comprehensive Cancer Network (NCCN) released the latest edition of “Guidelines for Clinical Practice in Soft Tissue Sarcomas (2nd Edition, 2016)”. Compared with previous versions, the GIST part of the new guidelines highlights the importance of wild-type GIST Standardization of diagnosis and treatment was made and partial adjustments were made to follow-up strategies for gastric minimal GIST <2 cm and evaluation of the malignant potential of GIST.